Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
AP-301 by Shanghai Alebund Pharmaceuticals for Hyperphosphatemia: Likelihood of Approval
AP-301 is under clinical development by Shanghai Alebund Pharmaceuticals and currently in Phase I for Hyperphosphatemia. According to GlobalData, Phase...